DENN domain containing 5AGenealiases: DEE49 · EIEE49 · RAB6IP1
Q-omics provides the consensus-scored DENND5A profile across patient tissues and cancer cell-line models. DENND5A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DENND5A is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, DENND5A RNA expression shows 20,604 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where DENND5A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DENND5A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DENND5A survival associations across molecular data types. DENND5A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (10) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DENND5A RNA expression–survival associations across cancer types. High DENND5A expression shows unfavorable associations in ACC, MESO, UVM, LIHC and KICH, but favorable associations in BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DENND5A RNA expression.
This table summarizes DENND5A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DENND5A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DENND5A shows lower tumor expression in BLCA, KICH and LUAD and higher tumor expression in HNSC, KIRC and LIHC. The HNSC box plot shows higher DENND5A RNA expression in tumor versus normal tissue (log2 FC = +1.079, t-test p < 0.001).
This table shows molecular features associated with DENND5A in patient tissues and cancer cell lines. In patient samples, DENND5A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DENND5A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
